GKOS (Glaukos) Issuance of Debt: $0.0 Mil (TTM As of Mar. 2026)


GKOS Glaukos Corp GKOS
80 GF Score
Price $152.66
GF Value $136.24
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Glaukos Issuance of Debt?

Glaukos GKOS +1.33% 80 Issuance of Debt is $0.0 Mil as of Mar. 2026. GuruFocus rates GKOS with a GF Score™ of 80/100 and a GF Value™ of $136.24 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Glaukos's Issuance of Debt for the three months ended in Mar. 2026 was $0.0 Mil.

Glaukos's Issuance of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was $0.0 Mil.

Glaukos Issuance of Debt Related Terms

Glaukos Issuance of Debt Historical Data

* Premium members only.

The historical data trend for Glaukos's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Glaukos Issuance of Debt Chart

Glaukos Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Issuance of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Glaukos Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
GKOS
80GF Score
Glaukos Corp GKOS
Issuance of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Glaukos Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Issuance of Debt →
What does a Issuance of Debt of $0.0 Mil mean?
Glaukos (GKOS) has a Issuance of Debt of $0.0 Mil as of Mar. 2026. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Glaukos and its competitors.
Is Glaukos' Issuance of Debt too high?
Glaukos' current Issuance of Debt is $0.0 Mil. Overall, Glaukos has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Glaukos' Issuance of Debt compare to BIO and BRKR?
Glaukos' Issuance of Debt of $0.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Issuance of Debt for a Medical Devices & Instruments company?
A good Issuance of Debt depends on the Medical Devices & Instruments industry context. However, Issuance of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Issuance of Debt mean?
A high Issuance of Debt can signal that a stock is expensive relative to its fundamentals. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Glaukos and its competitors. Glaukos's current Issuance of Debt is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glaukos stock overvalued right now?
Based on GuruFocus' analysis, Glaukos (GKOS) is currently considered Modestly Overvalued. The stock's GF Value™ is $136.24, compared to a current price of $152.66 — trading 12% above its estimated fair value. The current Issuance of Debt is $0.0 Mil. Glaukos' overall GF Score™ is 80/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Issuance of Debt calculated?
Issuance of Debt is calculated from a company's financial statements. For Glaukos (GKOS), the current Issuance of Debt is $0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Glaukos (GKOS) Overvalued in 2026?

Based on GuruFocus' analysis, Glaukos stock appears to be overvalued. The current stock price of $152.66 is trading 12% above its estimated GF Value™ of $136.24. GuruFocus considers Glaukos to be Modestly Overvalued.

Key valuation signals for GKOS:

  • Issuance of Debt: $0.0 Mil
  • GF Value™: $136.24 vs. price of $152.66 (12% above fair value)
  • GF Score™: 80/100 with 6 warning signs

No single metric tells the full story. See the GKOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Glaukos Business Description

Other Exchanges 6GJ:Germany
Address One Glaukos Way, Aliso Viejo, CA, USA, 92656
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
80GF Score

Get the complete analysis for GKOS

Issuance of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$152.66
Price
$136.24
GF Value